What is ALGS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.03B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ALGS?

P/E (TTM) is n/a and 52-week range is $3.98 to $13.69 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ALGS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ALGS?

The company profile lists revenue (TTM) near $19M, net income (TTM) near $-4.51B, EPS (TTM) near $-7.31 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Aligos Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in South San Francisco, California, US, 6.2M shares outstanding, ISIN US01626L2043 when available from company profile and filing metadata.

Aligos Therapeutics Inc

$ALGS

Health Care · Biotechnology

IR Run Scenarios

$5.34

+0.56%

Aligos Therapeutics Inc

$ALGS

Health Care · Biotechnology

IR Run Scenarios

$5.34

+0.56%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 82 full-time employees. The company went IPO on 2020-10-16. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.

Employees

82

Website

www.aligos.com/

IPO

2020-10-16

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US01626L2043

Headquarters

South San Francisco, California, US

Shares outstanding

6.2M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

42.18%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 82 full-time employees. The company went IPO on 2020-10-16. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.

Employees

82

Website

www.aligos.com/

IPO

2020-10-16

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)